Neurogene Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2018 |
|---|---|---|---|---|
| Revenue | $0 | $925.0K | $0 | $25.0M |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Gross Margin | — | — | — | — |
| Operating Expenses | ||||
| Research & Development | $75.0M | $60.9M | $44.4M | $41.8M |
| SG&A Expense | $28.3M | $22.6M | $11.2M | $15.8M |
| Operating Income | $-103.3M | $-82.6M | $-55.6M | $-32.6M |
| Operating Margin | — | -8,930.3% | — | -130.5% |
| Interest Expense | — | — | $12.0K | $4.0K |
| Pretax Income | $-90.4M | $-75.1M | $-36.3M | $-31.6M |
| Income Tax Expense | $0 | $0 | — | — |
| Net Income | $-90.4M | $-75.1M | $-36.3M | $-31.6M |
| Net Margin | — | -8,123.7% | — | -126.3% |
| EPS (Basic) | $-4.24 | $-4.28 | — | $-1.34 |
| EPS (Diluted) | $-4.24 | $-4.28 | — | $-1.34 |
| Shares Outstanding (Basic) | 21.3M | 17.6M | 12.8M | 23.5M |
| Shares Outstanding (Diluted) | 21.3M | 17.6M | 12.8M | 23.5M |
| Dividends Per Share | — | — | — | — |